Sage Journals: Discover world-class research

Abstract

Extranodal marginal zone B-cell lymphoma (ENMZL) of mucosa-associated lymphoid tissue (MALT), a rare subtype of B-cell lymphoma, is typically associated with Helicobacter pylori (H pylori) infection, especially in gastric cases. However, this article presents 2 unique cases of H pylori-negative colonic ENMZL, challenging the conventional understanding of the disease. The first case involves an 80-year-old male diagnosed with Stage 1E ENMZL in the descending colon, and the second describes a 74-year-old male with sigmoid colon ENMZL. Both cases lacked H pylori infection, adding complexity to their management. Accompanying these case studies is a comprehensive literature review, delving into the epidemiology, pathology, clinical features, diagnosis, and treatment of H pylori-negative ENMZL, with a focus on gastrointestinal involvement. This review highlights the importance of considering H pylori-negative cases in ENMZL diagnosis and management, illustrating the need for further research and individualized treatment approaches in this uncommon lymphoma subtype.

Keywords

extranodal marginal zone lymphoma extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue lymphoma MALT lymphoma gastroenterology hematology oncology

Introduction

Extranodal marginal zone B-cell lymphoma (ENMZL), also known as mucosa-associated lymphoid tissue (MALT) lymphoma, was first identified by Peter Isaacson and Dennis Wright in 1983.¹ This malignancy originates from B-cell lymphocytes in the marginal zone of secondary lymphoid follicles.² Extranodal marginal zone B-cell lymphoma accounts for approximately 5% to 8% of all B-cell lymphomas.^3,4 In the United States, the estimated incidence is 18.3 cases per million person-years.⁵ The most commonly affected site is the gastrointestinal tract, particularly the stomach. However, ENMZL can also occur in other locations, including the ocular adnexa, lung, lacrimal and salivary tracts, skin, breast, and thyroid.^6-19 Numerous studies have demonstrated a strong link between Helicobacter pylori (H pylori) infection and ENMZL,^20-26 with approximately 90% of patients with gastric MALT lymphoma testing positive for H pylori serology and culture.^20,27 However, other factors such as Chlamydia psittaci, Borrelia afzelii, and autoimmune disorders have also been implicated in the pathogenesis of ENMZL.^28-30 In this article, we present 2 cases of ENMZL in the colonic mucosa that tested negative for H pylori. In addition, we review the published literature and studies on gastrointestinal ENMZL not associated with H pylori infection.

Case Descriptions

Case 1

An 80-year-old male presented initially to the emergency room for abdominal fullness and bloating. A computed tomography (CT) of the abdomen and pelvis showed a 3 cm massive intraluminal filling defect in the duodenal bulb. An outpatient gastroenterology follow-up was recommended. An esophagogastroduodenoscopy (EGD) 1 month later showed grade C esophagitis, 2 gastric ulcers, excavated lesions in the duodenal bulb, and a few ulcers in the second portion of the duodenum. Biopsies did not reveal any neoplasms, and H pylori was negative. He was subsequently placed on a proton pump inhibitor for 6 weeks and underwent a follow-up EGD after 3 months with a screening colonoscopy. The EGD showed that the esophagitis, gastric, and duodenal ulcers had healed. Colonoscopy revealed multiple polyps in the ascending, transverse colon that showed villous adenoma on biopsy; however, a solitary sessile polyp in the descending polyp was found, for which the biopsy was positive for Stage 1E ENMZL. Helicobacter pylori was negative on biopsy. Fluorescence In Situ Hybridization (FISH) was positive for the MALT1 gene. CD21 and IgD were positive. Helicobacter pylori breath test was negative, and no H pylori was detected on stool studies. Patient was started on triple therapy (lansoprazole/amoxicillin/clarithromycin) and referred to oncology. Positron emission tomography (PET) scan revealed diffuse hypermetabolic activity throughout the colon. The patient was referred to oncology, and a wait and watch approach with close observation was undertaken. A follow colonoscopy 6 months later showed a completely resolved lesion in the descending colon.

Case 2

A 74-year-old male was initially referred to the gastroenterology clinic for a 6 month history of constipation with a change in caliber of his stools. There was no history of weight loss, loss of appetite, or indications of gastrointestinal bleeding. His last colonoscopy was 12 years prior to his presentation which he reported to be normal. His colonoscopy reveals a solitary 6 mm polyp in the sigmoid colon. This was removed with a cold snare. Histopathology showed it to be ENMZL. CD20, CD43, CD21, and bcl2 were positive. B-cell rearrangement was positive. MALT1 gene was not detected, and there was no translocation. No H pylori was seen. Stool samples were also negative for H pylori. Patient was referred to oncology. His PET scan was unremarkable, and flow cytometry was negative. His treatment was focused on managing symptoms of constipation, and it was decided that as this was resected, he will be closely followed up. On his 6 month follow-up, patient remains well and asymptomatic.

Discussion and Literature Review

Epidemiology

Approximately two thirds of all gastrointestinal ENMZL involve the stomach,^31,32 with about 90% of these gastric cases associated with H pylori infection.²⁰ However, studies on gastric ENMZL have identified a subset of patients without documented H pylori infection. Systematic reviews suggest that 5% to 10% of gastric lymphomas are H pylori-negative.^33,34 Rectal ENMZL, regardless of H pylori status, is rare, constituting less than 1% of colorectal malignancies. Extragastric H pylori-negative ENMZL is even rarer.^35-41 A literature review covering colorectal ENMZL cases published between 1993 and 2017 found that 74% were located in the rectum.⁴² Of these, only 19% of 44 tested cases were H pylori-positive. Our literature review from 1999 to 2017 identified 8 cases of H pylori-negative rectal ENMZL,^43-48 and 3 cases of H pylori-negative colonic ENMZL.⁴⁹ Single case reports of H pylori-negative ENMZL in the ileum and esophagus have also been documented.^50,51 Extranodal marginal zone B-cell lymphoma in the small intestine, known as immunoproliferative small intestinal disease (IPSID), is predominantly found in the Mediterranean and African regions, accounting for one third of the small intestinal lymphomas in these areas.⁵² Two studies reported no association between IPSID and H pylori.^52,53 No significant differences in age and sex have been observed between H pylori-negative and H pylori-positive ENMZL cases.⁵⁴

Pathology

Given the significant association of gastric ENMZL with H pylori and the fact that approximately 75% of H pylori-positive gastric ENMZL cases achieve complete remission (CR) with H pylori eradication (H pyloriE) therapy,^55,56 it is postulated that chronic H pylori infection stimulates lymphoid cells, leading to lymphoma development. Typically, ENMZL arises in sites originally devoid of lymphoid tissue, which accumulate lymphoid tissue in response to chronic infection or autoimmune disease.⁵⁷ Apart from H pylori, other bacteria, viruses, or autoimmune stimuli can also induce this chronic stimulation.

Helicobacter heilmannii (HH) has been implicated in the pathogenesis of ENMZL.⁵⁸ A study comparing 202 patients with H pylori gastritis to 202 with HH gastritis found that 3.4% of patients with HH gastritis had MALT lymphoma. This study also noted focal colonization in the antrum of patients with HH gastritis, in contrast to the diffuse form in H pylori gastritis.²⁵ Another study involving 5 patients with primary gastric low-grade MALT lymphoma, which responded to H pylori eradication therapy, associated these cases with HH gastritis diagnosed via the Warthin-Starry staining, serology, and culture.⁵⁸ The mechanisms of chronic inflammation triggering lymphoid cells in patients with HH remain largely unknown. Other organisms implicated in gastric ENMZL include hepatitis C virus, Borrelia burgdorferi, and C psittaci.⁵⁹ The incidental presence of these organisms in mild lymphoma tissue has not been thoroughly studied.⁶⁰ Campylobacter jejuni has been identified in cases of MALT lymphoma of the small intestine.^30,61

Autoimmune conditions are predominantly associated with extragastric ENMZL, especially in the salivary glands.^62-66 Systemic lupus erythematosus (SLE) and Sjogren’s syndrome have been linked with ENMZL. A pooled analysis of 12 case-control studies found that Sjogren’s syndrome was associated with a 6.5-fold risk of non-Hodgkin’s lymphoma and a 34% increased risk of marginal zone lymphoma, predominantly in the parotid gland.⁶⁷ A case series of 80 patients diagnosed with MALT lymphoma identified 13 cases of chronic autoimmune thyroiditis. Of these, 4 had mild lymphoma in the stomach and 1 in the small intestine. Interestingly, 7 of the 13 patients had an H pylori infection, although the association with chronic autoimmune thyroiditis remains unclear.⁶⁸

Four chromosomal translocations are typically observed in ENMZL: t(11;18)(q21;q21), t(14;18)(q32;q21), t(1;14)(p22;q32), and t(3;14)(p14.1;q32). These translocations activate the nuclear factor kappa B (NF-κB) through the BCL10/MALT1 signal complex, enhancing the survival of ENMZL cells.⁵⁷ They have been extensively studied as prognostic factors and indicators of lymphomas unresponsive to H pylori eradication therapy.^69,70 About 30% of all MALT lymphoma cases feature the t(11;18)(q21;21) translocation, which is usually unresponsive to H pyloriE and significantly associated with H pylori-negative lymphomas.^34,60 These lymphomas are often advanced but rarely undergo high-grade transformation.^69,71 Notably, this translocation is the most common chromosomal abnormality in ENMZL cases with a strong association with the CagA-positive strain of H pylori.⁷²

Clinical Features

The stomach is the most common site of involvement for ENMZL, although it can also affect other parts of the gastrointestinal tract. Patients with gastric ENMZL may be asymptomatic or present with symptoms such as epigastric pain, anorexia, weight loss, occult blood loss, or symptoms indicative of reflux disease.⁷³ Small intestinal lesions often manifest as diarrhea, abdominal pain, or malabsorption.^30,74,75 In advanced stages, obstruction or ascites may develop. However, classic B symptoms like fever, night sweats, and weight loss are rare in gastric ENMZL.⁷⁶ Extranodal marginal zone B-cell lymphoma associated with H pylori may be clinically indistinguishable from those not associated with this bacterium. Although H pylori causes gastritis, ENMZL does not typically present with gastritis symptoms. In cases with a concerning history, clinical features of autoimmune diseases such as Sjogren’s syndrome or SLE should be evaluated.

A systematic review encompassing 38 studies with a total of 2000 patients, comparing high-grade and low-grade lymphomas, found that alarm symptoms (anemia, hemorrhage, vomiting, and weight loss) were significantly more prevalent in those with high-grade lymphomas.⁷⁷ The correlation with H pylori status in these cases was not established. Rectal MALT lymphomas can be asymptomatic, but they may also present with rectal bleeding, hematochezia, and constipation.^42,78 A literature review of multiple case reports indicated that the most common clinical findings in these cases are hematochezia followed by positive fecal occult blood tests.⁴²

Diagnosis

To diagnose ENMZL, histopathology, immunophenotyping, and genetic analysis of biopsy samples are crucial. Endoscopic examination of gastric MALT lymphomas reveals no significant differences between H pylori-positive and H pylori-negative cases.^42,79 The non-specific nature of these endoscopic findings is evident across various types of lymphomas. For instance, in a study of over 1000 patients, 52% of lesions were ulcerative, 23.5% hypertrophic, 12.7% appeared normal, and 9.7% were exophytic.⁷⁷ When no obvious mass is detected but suspicion for a submucosal lesion remains high, endoscopic ultrasound-guided fine needle aspiration or submucosal resection may offer a more sensitive method for sample collection.^80-82

Colorectal ENMZL often appears as a solitary polypoid nodule, but in 30% of cases, multiple lesions are observed.⁴² These are predominantly located in the rectum, and when present in the colon, they are more likely to be proximal to the hepatic flexure.⁴² In some cases, lesions are elevated, necessitating endoscopic ultrasonography.⁴⁴ Endoscopic ultrasonography and magnifying endoscopy are also valuable in staging ENMZL and assessing clinical remission.

Testing for H pylori infection is a critical component of ENMZL management, as H pylori eradication therapy has been shown to significantly contribute to the remission of MALT lymphoma.^83-89 Helicobacter pylori testing can be performed through biopsy or culture of biopsies. Non-invasive tests include urea breath testing or stool antigen testing, which detect active infection. Serology can indicate both active and past infections. For C jejuni, associated with IPSID, serological testing is used. Additional autoimmune conditions like Sjogren’s syndrome or SLE can also be investigated through serology.

Testing for MALT1 translocation, such as t(11;18), is typically conducted using the polymerase chain reaction (PCR) techniques. Comprehensive imaging of the chest, abdomen, and pelvis is necessary to evaluate for potential distant spread.

Treatment

Gastric ENMZL and Helicobacter pylori eradication therapy

The European Gastrointestinal Lymphoma Study recommends H pyloriE therapy for all patients with H pylori-negative gastric ENMZL, based on the possibility of false-negative tests failing to detect H pylori or HH.^58,90 A retrospective analysis of 11 patients with H pylori-negative gastric ENMZL from 1998 to 2009 showed that 3 out of 11 responded completely to H pyloriE, whereas another 3 showed successful outcomes with H pyloriE combined with radiotherapy.⁹¹ This analysis included 4 other studies with 31 patients, where 10 (32%) showed complete response to H pyloriE. Reports of complete eradication vary from 13.6% to 83% across various studies.^55,92,93 In a study of 17 H pylori-negative patients treated initially with H pyloriE, 5 achieved CR, and another 5 non-responders achieved CR with added radiotherapy.⁹⁴ This study noted that non-responders often had multiple lesions, and all lesions were confined to the gastric body, suggesting lesion location can predict response to H pyloriE.^55,79,95-97 The presence of t(11;18) translocation has been linked to significant resistance to H pyloriE.^{46,55,60,69,96,98} No significant differences were observed in relapse rates between H pylori-positive and H pylori-negative ENMZL post-H pyloriE treatment.⁹⁹

Gastric extranodal marginal zone B-cell lymphoma and radiation therapy

Radiation therapy (RT) has been effective in achieving CR for early-stage lymphoma. A prospective study showed that 14 out of 22 patients with stage I/II H pylori-negative ENMZL treated with RT achieved complete response, with a 5-year overall survival rate of 91%.¹⁰⁰ The study reported better responses to RT compared with H pyloriE.⁵³ Another study found a 92.9% regression rate in patients with H pylori-negative and H pyloriE-resistant ENMZL treated with RT.⁵³ Other studies have noted a 40% overall relapse rate, usually at distant mucosal sites.^101-105 Long-term follow-up revealed only 1 patient developing distant recurrence out of 13 who received RT.¹⁰⁶

Gastric extranodal marginal zone B-cell lymphoma and chemotherapy

Surveillance, Epidemiology, and End Results (SEER) studies between 1997 and 2007 indicated better responses to rituximab than to combination chemotherapy for gastric ENMZL.¹⁰⁷ Older studies showed a 64% response rate to rituximab.¹⁰⁸ An observational study found that patients treated with combination chemotherapy (alkylating agents + rituximab) responded better than those treated with only alkylating agents or rituximab alone.¹⁰⁹ A case series of 26 patients, 56% of whom were H pylori-negative and had been previously treated with H pyloriE, surgery, or alkylating agents, found that 12 patients achieved complete response to rituximab.¹¹⁰

Extragastric extranodal marginal zone B-cell lymphoma treatment modalities

Limited data are available on H pylori-negative colorectal MALT lymphomas. Various treatments include irrigation therapy, chemotherapy, surgery, radiotherapy, and endomucosal resection (EMR).¹¹¹ Management of early-stage IPSID can involve local regional radiotherapy, surgery, rituximab, or observation. A trial of H pyloriE is sometimes suggested even if H pylori is negative.¹¹¹ Antibiotics have shown mixed effectiveness in treating extragastric MALT lymphomas. Regression of rectal MALT lymphomas with H pyloriE has been observed in several case reports.^43,45,47-49 RT has been effective in H pylori-negative ENMZL, and chemotherapy with rituximab has shown promise, although studies have not always defined H pylori status.^112-118

Conclusions

This case reports and review sheds light on the complexities of H pylori-negative MALT-Associated Extranodal Marginal Zone Lymphoma, challenging traditional understandings of its association with H pylori infection. The unique case studies presented emphasize the importance of considering ENMZL in differential diagnoses regardless of H pylori status and underscore the need for individualized treatment approaches. This work highlights the necessity for further research into this rare lymphoma subtype to improve diagnostic accuracy and treatment effectiveness.

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethics Approval

Our institution does not require ethical approval for reporting individual cases or case series.

Informed Consent

Verbal informed consent was obtained from the patient for their anonymized information to be published in this article.

ORCID iD

Akash Patel

References

Isaacson

Wright

DH.

Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer. 1983;52:1410-1416. doi:10.1002/1097-0142(19831015)52:8<1410::aid-cncr2820520813>3.0.co;2-3

Thieblemont

Zucca

Clinical aspects and therapy of gastrointestinal MALT lymphoma. Best Pract Res Clin Haematol. 2017;30(1-2):109-117. doi:10.1016/j.beha.2017.01.002

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood. 1997;89: 3909-3918.

Olszewski

Castillo

JJ.

Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database. Cancer. 2013;119:629-638. doi:10.1002/cncr.27773

Khalil

Morton

Devesa

, et al. Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site. Br J Haematol. 2014;165(1):67-77. doi:10.1111/bjh.12730

Zucca

Conconi

Pedrinis

, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003;101:2489-2495. doi:10.1182/blood-2002-04-1279

Tsang

Gospodarowicz

Pintilie

, et al. Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys. 2001;50:1258-1264. doi:10.1016/s0360-3016(01)01549-8

Iwamoto

DeAngelis

Abrey

LE.

Primary dural lymphomas: a clinicopathologic study of treatment and outcome in eight patients. Neurology. 2006;66:1763-1765. doi:10.1212/01.wnl.0000218284.23872.eb

Giannini

Judkins

, et al. Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma. J Clin Oncol. 2005;23:5718-5727. doi:10.1200/jco.2005.17.624

10.

George

Ozsahin

Janzer

, et al. Primary intracranial dural lymphoma of mucosa-associated lymphoid tissue (MALT) type: report of one case and review of the literature. Bull Cancer. 2005;92(7):E51-E56.

11.

Welsh

Howard

Hong

Lucas

Reding

DJ.

Synchronous bilateral breast mucosa-associated lymphoid tissue lymphomas addressed with primary radiation therapy. Am J Clin Oncol. 2006;29(6):634-635. doi:10.1097/01.coc.0000248930.12423.2e

12.

Ikeda

Morii

Yamauchi

, et al. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type developing in gonarthritis deformans. J Clin Oncol. 2007;25: 4310-4312. doi:10.1200/jco.2007.12.7092

13.

Servitje

Gallardo

Estrach

, et al. Primary cutaneous marginal zone B-cell lymphoma: a clinical, histopathological, immunophenotypic and molecular genetic study of 22 cases. Br J Dermatol. 2002;147(6):1147-1158. doi:10.1046/j.1365-2133.2002.04961.x

14.

Ferry

Fung

Zukerberg

, et al. Lymphoma of the ocular adnexa: a study of 353 cases. Am J Surg Pathol. 2007;31(2): 170-184. doi:10.1097/01.pas.0000213350.49767.46

15.

Stefanovic

Lossos

IS.

Extranodal marginal zone lymphoma of the ocular adnexa. Blood. 2009;114:501-510. doi:10.1182/blood-2008-12-195453

16.

Troch

Formanek

Streubel

Müllauer

Chott

Raderer

Clinicopathological aspects of mucosa-associated lymphoid tissue (MALT) lymphoma of the parotid gland: a retrospective single-center analysis of 28 cases. Head Neck. 2011; 33(6):763-767. doi:10.1002/hed.21533

17.

Vazquez

Khan

Sanghvi

, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a population-based study from 1994 to 2009. Head Neck. 2015;37(1):18-22. doi:10.1002/hed.23543

18.

Jackson

Mian

Kalpadakis

, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of the salivary glands: a multicenter, international experience of 248 patients (IELSG 41). Oncologist. 2015;20(10):1149-1153. doi:10.1634/theoncologist.2015-0180

19.

Teckie

Chelius

, et al. Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma. Ann Oncol. 2017;28:1064-1069. doi:10.1093/annonc/mdx025

20.

Wotherspoon

Ortiz-Hidalgo

Falzon

, et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 1991;338:1175-1176. doi:10.1016/0140-6736(91)92035-z

21.

Parsonnet

Hansen

Rodriguez

, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 1994;330:1267-1271. doi:10.1056/nejm199405053301803

22.

Eck

Schmausser

Haas

Greiner

Czub

Müller-Hermelink

HK.

MALT-type lymphoma of the stomach is associated with Helicobacter pylori strains expressing the CagA protein. Gastroenterology. 1997;112(5):1482-1486. doi:10.1016/s0016-5085(97)70028-3

23.

Chang

Chen

Yang

Lin

Chang

Wang

JT.

Isolation of a Helicobacter pylori protein, FldA, associated with mucosa-associated lymphoid tissue lymphoma of the stomach. Gastroenterology. 1999;117(1):82-88. doi:10.1016/s0016-5085(99)70553-6

24.

Mazzucchelli

Blaser

Kappeler

, et al. BCA-1 is highly expressed in Helicobacter pylori-induced mucosa-associated lymphoid tissue and gastric lymphoma. J Clin Invest. 1999; 104(10):R49-R54. doi:10.1172/jci7830

25.

Stolte

Kroher

Meining

Morgner

Bayerdörffer

Bethke

A comparison of Helicobacter pylori and H. heilmannii gastritis. A matched control study involving 404 patients. Scand J Gastroenterol. 1997;32(1):28-33. doi:10.3109/00365529709025059

26.

Lin

Tsai

Kuo

, et al. Translocation of Helicobacter pylori CagA into Human B lymphocytes, the origin of mucosa-associated lymphoid tissue lymphoma. Cancer Res. 2010;70: 5740-5748. doi:10.1158/0008-5472.Can-09-4690

27.

Asenjo

Gisbert

JP.

[Prevalence of Helicobacter pylori infection in gastric MALT lymphoma: a systematic review]. Rev Esp Enferm Dig. 2007;99(7):398-404. doi:10.4321/s1130-01082007000700006

28.

Husain

Roberts

Pro

, et al. Meta-analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics. Cancer. 2007;110:809-815. doi:10.1002/cncr.22843

29.

Ferreri

Dolcetti

Dognini

, et al. Chlamydophila psittaci is viable and infectious in the conjunctiva and peripheral blood of patients with ocular adnexal lymphoma: results of a single-center prospective case-control study. Int J Cancer. 2008;123:1089-1093. doi:10.1002/ijc.23596

30.

Al-Saleem

Al-Mondhiry

Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. Blood. 2005;105:2274-2280. doi:10.1182/blood-2004-07-2755

31.

Zucca

Roggero

Bertoni

Cavalli

Primary extranodal non-Hodgkin’s lymphomas. Part 1: gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol. 1997;8(8):727-737. doi:10.1023/a:1008282818705

32.

Gisbert

Calvet

Review article: common misconceptions in the management of Helicobacter pylori-associated gastric MALT-lymphoma. Aliment Pharmacol Ther. 2011;34(9):1047-1062. doi:10.1111/j.1365-2036.2011.04839.x

33.

Zullo

Hassan

Ridola

, et al. Eradication therapy in Helicobacter pylori-negative, gastric low-grade mucosa-associated lymphoid tissue lymphoma patients: a systematic review. J Clin Gastroenterol. 2013;47(10):824-827. doi:10.1097/MCG.0b013e318286ff72

34.

Liu

Raderer

, et al. High incidence of t(11;18)(q21; q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood. 2003;101:2547-2550. doi:10.1182/blood-2002-10-3167

35.

Shepherd

Hall

Coates

Levison

DA.

Primary malignant lymphoma of the colon and rectum. A histopathological and immunohistochemical analysis of 45 cases with clinicopathological correlations. Histopathology. 1988;12(3):235-252. doi:10.1111/j.1365-2559.1988.tb01939.x

36.

Fan

Changchien

Wang

, et al. Primary colorectal lymphoma. Dis Colon Rectum. 2000;43:1277-1282. doi:10.1007/bf02237436

37.

Dosumu

EA.

Side-effects of drugs used in directly observed treatment short-course in newly diagnosed pulmonary tuberculosis subjects in Nigerians: a controlled clinical study. Niger Postgrad Med J. 2002;9(1):34-37.

38.

Nagashima

Takeda

Maeda

Ohno

Takahashi

Regression of duodenal mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori. Gastroenterology. 1996;111(6):1674-1678. doi:10.1016/s0016-5085(96)70032-x

39.

Alkan

Karcher

Newman

, et al. Regression of salivary gland MALT lymphoma after treatment for Helicobacter pylori. Lancet. 1996;348:268-269. doi:10.1016/s0140-6736(05)65578-x

40.

Fischbach

Tacke

Greiner

, et al. Regression of immunoproliferative small intestinal disease after eradication of Helicobacter pylori. Lancet. 1997;349:31-32. doi:10.1016/s0140-6736(05)62165-4

41.

Bickel

Eitan

Tsilman

Cohen

HI.

Low-grade B cell lymphoma of mucosa-associated lymphoid tissue (MALT) arising in the gallbladder. Hepatogastroenterology. 1999;46(27):1643-1646.

42.

Won

Kim

Park

Kim

JY.

Clinical features, treatment and outcomes of colorectal mucosa-associated lymphoid tissue (MALT) lymphoma: literature reviews published in English between 1993 and 2017. Cancer Manag Res. 2019;11:8577-8587. doi:10.2147/cmar.S214197

43.

Nomura

Uchimi

Abue

, et al. [Regression of MALT lymphoma of the rectum after Helicobacter pylori eradication therapy in a patient negative for Helicobacter pylori]. Nihon Shokakibyo Gakkai Zasshi. 2010;107(9):1466-1473.

44.

Okamura

Suga

Iwaya

, et al. Helicobacter pylori-negative primary rectal MALT lymphoma: complete remission after radiotherapy. Case Rep Gastroenterol. 2012;6(2):319-327. doi:10.1159/000339461

45.

Nakase

Okazaki

Ohana

, et al. The possible involvement of micro-organisms other than Helicobacter pylori in the development of rectal MALT lymphoma in H. pylori-negative patients. Endoscopy. 2002;34(4):343-346. doi:10.1055/s-2002-23643

46.

Ohara

Kitadai

Onoyama

, et al. Regression of rectal MALT lymphoma after antibiotic treatment in a patient negative for Helicobacter pylori. Clin J Gastroenterol. 2012;5(1): 59-63. doi:10.1007/s12328-011-0270-5

47.

Inoue

Chiba

Regression of MALT lymphoma of the rectum after anti-H. pylori therapy in a patient negative for

H. pylori. Gastroenterology. 1999;117(2):514-515. doi:10.1053/gast.1999.0029900514b

48.

Hisabe

Imamura

Furukawa

, et al. Regression of CD5-positive and Helicobacter pylori-negative mucosa-associated lymphoid tissue lymphoma of the rectum after administration of antibiotics: report of a case. Dis Colon Rectum. 2002;45(9):1267-1270. doi:10.1007/s10350-004-6404-9

49.

Kikuchi

Matsui

Hisabe

, et al. Deep infiltrative low-grade MALT (mucosal-associated lymphoid tissue) colonic lymphomas that regressed as a result of antibiotic administration: endoscopic ultrasound evaluation. J Gastroenterol. 2005; 40(8):843-847. doi:10.1007/s00535-005-1639-3

50.

Lin

Lai

Tsai

, et al. Extranodal marginal zone B-cell lymphoma of the gastrointestinal tract sparing only the esophagus: a case report. Turk J Gastroenterol. 2012;23(1): 58-62. doi:10.4318/tjg.2012.0371

51.

Terada

Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) of the ileum in a 35-year-old Japanese woman. Int J Clin Exp Pathol. 2013; 6(5):951-956.

52.

Ewers

Sheffler

Wang

, et al. Immunoproliferative small intestinal disease associated with overwhelming polymicrobial gastrointestinal infection with transformation to diffuse large B-cell lymphoma. Am J Trop Med Hyg. 2016;94:1177-1181. doi:10.4269/ajtmh.15-0831

53.

Malekzadeh

Kaviani

Tabei

, et al. Lack of association between Helicobacter pylori infection and immunoproliferative small intestinal disease. Arch Iran Med. 1999;2:1-4.

54.

Akamatsu

Mochizuki

Okiyama

Matsumoto

Miyabayashi

Ota

Comparison of localized gastric mucosa-associated lymphoid tissue (MALT) lymphoma with and without Helicobacter pylori infection. Helicobacter. 2006; 11(2):86-95. doi:10.1111/j.1523-5378.2006.00382.x

55.

Nakamura

Sugiyama

Matsumoto

, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012;61(4):507-513. doi:10.1136/gutjnl-2011-300495

56.

Zullo

Hassan

Ridola

Repici

Manta

Andriani

Gastric MALT lymphoma: old and new insights. Ann Gastroenterol. 2014;27(1):27-33.

57.

Sagaert

De Wolf-Peeters

Noels

Baens

The pathogenesis of MALT lymphomas: where do we stand?

Leukemia. 2007;21(3):389-396. doi:10.1038/sj.leu.2404517

58.

Morgner

Lehn

Andersen

, et al. Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology. 2000;118(5):821-828. doi:10.1016/s0016-5085(00)70167-3

59.

Suarez

Lortholary

Hermine

, et al. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107:3034-3044. doi:10.1182/blood-2005-09-3679

60.

Nakamura

Bacon

, et al. Clinical impact of genetic aberrations in gastric MALT lymphoma: a comprehensive analysis using interphase fluorescence in situ hybridisation. Gut. 2007;56(10):1358-1363. doi:10.1136/gut.2007.123729

61.

Lecuit

Abachin

Martin

, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med. 2004;350:239-248. doi:10.1056/NEJMoa031887

62.

Nocturne

Mariette

Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol. 2015;168(3):317-327. doi:10.1111/bjh.13192

63.

Zintzaras

Voulgarelis

Moutsopoulos

HM.

The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005;165:2337-2344. doi:10.1001/archinte.165.20.2337

64.

Ambrosetti

Zanotti

Pattaro

, et al. Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection. Br J Haematol. 2004;126:43-49. doi:10.1111/j.1365-2141.2004.04993.x

65.

Aozasa

Hashimoto’s thyroiditis as a risk factor of thyroid lymphoma. Acta Pathol Jpn. 1990;40(7):459-468.

66.

Ruiz

IF.

Promising new therapy for lysosomal acid lipase deficiency. Nat Rev Cardiol. 2015;12(12):683-683.

67.

Ekström Smedby

Vajdic

Falster

, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111:4029-4038. doi:10.1182/blood-2007-10-119974

68.

Troch

Woehrer

Streubel

, et al. Chronic autoimmune thyroiditis (Hashimoto’s thyroiditis) in patients with MALT lymphoma. Ann Oncol. 2008;19(7):1336-1339. doi:10.1093/annonc/mdn049

69.

Liu

Ruskone-Fourmestraux

, et al. T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology. 2002;122: 1286-1294. doi:10.1053/gast.2002.33047

70.

Liu

Ruskon-Fourmestraux

Lavergne-Slove

, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001;357:39-40. doi:10.1016/s0140-6736(00)03571-6

71.

Inagaki

Nakamura

, et al. Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter pylori eradication and detection of API2-MALT1 fusion. Am J Surg Pathol. 2004;28(12):1560-1567. doi:10.1097/00000478-200412000-00003

72.

Liu

Attygalle

, et al. Variable frequencies of t(11;18)(q21; q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma. Blood. 2003;102:1012-1018. doi:10.1182/blood-2002-11-3502

73.

Kalpadakis

Pangalis

Vassilakopoulos

, et al. Clinical aspects of malt lymphomas. Curr Hematol Malig Rep. 2014;9(3):262-272.

74.

Gilinsky

Novis

Wright

Dent

King

Marks

IN.

Immunoproliferative small-intestinal disease: clinical features and outcome in 30 cases. Medicine (Baltimore). 1987;66(6):438-446.

75.

Al-Bahrani

Al-Mondhiry

Bakir

, et al. Clinical and pathologic subtypes of primary intestinal lymphoma. Experience with 132 patients over a 14-year period. Cancer. 1983;52:1666-1672. doi:10.1002/1097-0142(19831101)52:9<1666::aid-cncr2820520920>3.0.co;2-p

76.

Kahl

BS.

Update: gastric MALT lymphoma. Curr Opin Oncol. 2003;15:347-352.

77.

Zullo

Hassan

Andriani

, et al. Primary low-grade and high-grade gastric MALT-lymphoma presentation. J Clin Gastroenterol. 2010;44(5):340-344. doi:10.1097/MCG.0b013e3181b4b1ab

78.

Kelley

SR.

Mucosa-associated lymphoid tissue (MALT) variant of primary rectal lymphoma: a review of the English literature. Int J Colorectal Dis. 2017;32(3):295-304.

79.

Ruskoné-Fourmestraux

Lavergne

Aegerter

, et al. Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut. 2001;48(3):297-303. doi:10.1136/gut.48.3.297

80.

Chang

Katz

Durbin

, et al. Endoscopic ultrasound-guided fine-needle aspiration. Gastroint Endosc. 1994;40: 694-699.

81.

Wiersema

Kochman

Cramer

Tao

Wiersema

LM.

Endosonography-guided real-time fine-needle aspiration biopsy. Gastrointest Endosc. 1994;40(6):700-707.

82.

Karcher

DS.

Clinically unsuspected Hodgkin disease presenting initially in the bone marrow of patients infected with the human immunodeficiency virus. Cancer. 1993;71:1235-1238.

83.

Wotherspoon

Doglioni

Diss

, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993;342:575-577. doi:10.1016/0140-6736(93)91409-f

84.

Savio

Franzin

Wotherspoon

, et al. Diagnosis and posttreatment follow-up of Helicobacter pylori-positive gastric lymphoma of mucosa-associated lymphoid tissue: histology, polymerase chain reaction, or both? Blood. 1996;87:1255-1260.

85.

Weber

Dimopoulos

Anandu

, et al. Regression of gastric lymphoma of mucosa-associated lymphoid tissue with antibiotic therapy for Helicobacter pylori. Gastroenterology. 1994;107:1835-1838.

86.

Roggero

Zucca

Pinotti

, et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med. 1995;122:767-769. doi:10.7326/0003-4819-122-10-199505150-00006

87.

Carlson

Yokoo

Vanagunas

Progression of gastritis to monoclonal B-cell lymphoma with resolution and recurrence following eradication of Helicobacter pylori. JAMA. 1996;275:937-939.

88.

Fischbach

Goebeler-Kolve

Dragosics

Greiner

Stolte

Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut. 2004;53(1):34-37. doi:10.1136/gut.53.1.34

89.

Okame

Takaya

Sato

, et al. Complete regression of early-stage gastric diffuse large B-cell lymphoma in an HIV-1-infected patient following Helicobacter pylori eradication therapy. Clin Infect Dis. 2014;58(10):1490-1492. doi:10.1093/cid/ciu111

90.

Ruskoné-Fourmestraux

Fischbach

Aleman

, et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut. 2011;60(6):747-758. doi:10.1136/gut.2010.224949

91.

Park

Kim

Yang

, et al. Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma. World J Gastroenterol. 2010;16:2158-2162. doi:10.3748/wjg.v16.i17.2158

92.

Nakamura

Matsumoto

, et al. Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a clinicopathologic and molecular study with reference to antibiotic treatment. Cancer. 2006;107:2770-2778. doi:10.1002/cncr.22326

93.

Raderer

Streubel

Wöhrer

Häfner

Chott

Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut. 2006;55(5):616-618. doi:10.1136/gut.2005.083022

94.

Asano

Iijima

Terai

, et al. Eradication therapy is effective for Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma. Tohoku J Exp Med. 2012;228:223-227. doi:10.1620/tjem.228.223

95.

Isaacson

PG.

Update on MALT lymphomas. Best Pract Res Clin Haematol. 2005;18:57-68. doi:10.1016/j.beha.2004.08.003

96.

Choi

Kim

Paik

, et al. Characteristics of Helicobacter pylori-positive and Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma and their influence on clinical outcome. Helicobacter. 2013;18(3): 197-205. doi:10.1111/hel.12033

97.

Chung

Kim

, et al. Long-term clinical outcome of helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma is comparable to that of H. pylori-positive lymphoma. J Clin Gastroenterol. 2009;43(4):312-317. doi:10.1097/MCG.0b013e31816a48f8

98.

Lévy

Copie-Bergman

Gameiro

, et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol. 2005;23:5061-5066. doi:10.1200/jco.2005.05.660

99.

Gong

Ahn

Jung

, et al. Helicobacter pylori eradication therapy is effective as the initial treatment for patients with H. pylori-negative and disseminated gastric mucosa-associated lymphoid tissue lymphoma. Gut Liver. 2016;10:706-713. doi:10.5009/gnl15510

100.

Okada

Takemoto

Kawahara

, et al. A prospective analysis of efficacy and long-term outcome of radiation therapy for gastric mucosa-associated lymphoid tissue lymphoma. Digestion. 1956;86:179-186.

101.

Tsang

Gospodarowicz

Pintilie

, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2003;21:4157-4164. doi:10.1200/jco.2003.06.085

102.

Tsai

Silver

Stevenson

Mauch

PM.

Role of radiation therapy in the treatment of stage I/II mucosa-associated lymphoid tissue lymphoma. Ann Oncol. 2007;18(4):672-678. doi:10.1093/annonc/mdl468

103.

Thieblemont

Bastion

Berger

, et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol. 1997;15(4):1624-1630. doi:10.1200/jco.1997.15.4.1624

104.

Zinzani

Magagnoli

Galieni

, et al. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol. 1999;17(4):1254. doi:10.1200/jco.1999.17.4.1254

105.

Vrieling

de Jong

Boot

de Boer

Wegman

Aleman

BM.

Long-term results of stomach-conserving therapy in gastric MALT lymphoma. Radiother Oncol. 2008; 87(3):405-411. doi:10.1016/j.radonc.2008.02.012

106.

Tomita

Kodaira

Tachibana

Nakamura

Mizoguchi

Takada

Favorable outcomes of radiotherapy for early-stage mucosa-associated lymphoid tissue lymphoma. Radiother Oncol. 2009;90(2):231-235. doi:10.1016/j.radonc.2008.12.004

107.

Olszewski

Castillo

JJ.

Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database. Ann Oncol. 2013;24(5):1352-1359. doi:10.1093/annonc/mds644

108.

Conconi

Martinelli

Thiéblemont

, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102:2741-2745. doi:10.1182/blood-2002-11-3496

109.

Amiot

Lévy

Copie-Bergman

, et al. Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational study. Aliment Pharmacol Ther. 2014;39(6):619-628. doi:10.1111/apt.12635

110.

Martinelli

Laszlo

Ferreri

, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin’s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005;23:1979-1983. doi:10.1200/jco.2005.08.128

111.

Fine

Stone

MJ.

Alpha-heavy chain disease, Mediterranean lymphoma, and immunoproliferative small intestinal disease: a review of clinicopathological features, pathogenesis, and differential diagnosis. Am J Gastroenterol. 1999;94(5):1139-1152. doi:10.1111/j.1572-0241.1999.01057.x

112.

Ureshino

Ito

Treatment choice for primary rectal MALT lymphoma. QJM. 2019;112:637-638.

113.

Ray

Jia

Yao

, et al. A stress-responsive RNA switch regulates VEGFA expression. Nature. 2009;457:915-919. doi:10.1038/nature07598

114.

Ahlawat

Kanber

Charabaty-Pishvaian

, et al. Primary mucosa-associated lymphoid tissue (MALT) lymphoma occurring in the rectum: a case report and review of the literature. South Med J. 2006;99(12):1378-1384. doi:10.1097/01.smj.0000215855.98512.9d

115.

Tanaka

Ohta

Kaji

Kosaka

Murakami

EMR of mucosa-associated lymphoid tissue lymphoma of the rectum. Gastrointest Endosc. 2003;57(7):956-959. doi:10.1016/s0016-5107(03)70039-x

116.

Goda

Gospodarowicz

Pintilie

, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer. 2010; 116:3815-3824. doi:10.1002/cncr.25226

117.

Chihara

Kagami

Oki

, et al. R-CHOP therapy for MALT lymphoma of the rectum. Eur J Haematol. 2010;84: 84-86. doi:10.1111/j.1600-0609.2009.01346.x

118.

Kagawa

Okamura

Okamoto

, et al. [Successful rituximab monotherapy in a patient with mucosa-associated lymphoid tissue lymphoma of the rectum with trisomy 3, 18]. Nihon Shokakibyo Gakkai Zasshi. 2010;107(4):612-619.

H pylori -Negative MALT-Associated Extranodal Marginal Zone Lymphoma: A Comprehensive Case Report and Literature Review

Abstract

Keywords

Introduction

Case Descriptions

Case 1

Case 2

Discussion and Literature Review

Epidemiology

Pathology

Clinical Features

Diagnosis

Treatment

Gastric ENMZL and Helicobacter pylori eradication therapy

Gastric extranodal marginal zone B-cell lymphoma and radiation therapy

Gastric extranodal marginal zone B-cell lymphoma and chemotherapy

Extragastric extranodal marginal zone B-cell lymphoma treatment modalities

Conclusions

Footnotes

Declaration of Conflicting Interests

Funding

Ethics Approval

Informed Consent

ORCID iD

References